It looks like the GenesisCare arrangement is already generating...

It looks like the GenesisCare arrangement is already generating income for Noxopharm; income that will grow substantially once GenesisCare expands operations in Europe and the USA

Some excerpts from the announcement:

Dr Gisela Mautner, Chief Medical Officer of Noxopharm, stated: “The heavy lifting has been done for several key aspects of bringing Veyonda® to market. We have shown that Veyonda® is very well tolerated and safe in the patients who have participated in our studies so far. It has also shown to be safe in our compassionate use program which involves even more progressed patients in many cases.

Graham Kelly PhD, Noxopharm CEO, said: “Veyonda® is emerging as a potentially very valuable new therapy. The largest single market sector in oncology is end-stage metastatic cancer, a point at which almost every patient with metastatic cancer eventually finds themselves and is left with few treatment choices beyond palliative care. That very substantial unmet need with limited competition is where we are positioning Veyonda® in the first instance.”

The Company currently is taking steps to ensure that the production line involving raw materials supply, drug synthesis and final product manufacture remains secure ahead of the DARRT-2 study and the growing compassionate use program being conducted in cooperation with GenesisCare.